CRBN expression in HOVON-65/GMMG-HD4. Shown is CRBN expression in relation to PFS and OS Kaplan-Meier curves of CRBN expression in relation to survival in thalidomide-treated patients (A-B) and in relation to bortezomib-treated patients (C-D). PFS is shown at left; OS on the right. Log-rank P values are shown in the right corner of each panel. Broken lines indicate CRBN expression levels below the median and solid lines indicate expression levels above the median. Remaining patients at risk are shown above the x-axis (PFS at 1, 2, 3, and 4 years and OS at 1, 2, 3, 4, and 5 years). The median CRBN expression was determined on the combined data of both thalidomide- and bortezomib-treated patients: 45 of 96 patients were below the median in the thalidomide set, whereas 50 of 95 were below the median in the bortezomib set.